Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69.8M
-
Number of holders
-
121
-
Total 13F shares, excl. options
-
56.8M
-
Shares change
-
+737K
-
Total reported value, excl. options
-
$1.68B
-
Value change
-
+$23.2M
-
Put/Call ratio
-
0.04
-
Number of buys
-
61
-
Number of sells
-
-48
-
Price
-
$29.63
Significant Holders of Kymera Therapeutics, Inc. - Common Stock (KYMR) as of Q1 2023
143 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock as of Q1 2023.
Kymera Therapeutics, Inc. - Common Stock (KYMR) has 121 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.8M shares
of 69.8M outstanding shares and own 81.46% of the company stock.
Largest 10 shareholders include Atlas Venture Life Science Advisors, LLC (5.86M shares), BVF INC/IL (4.74M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.67M shares), WELLINGTON MANAGEMENT GROUP LLP (4.29M shares), Avoro Capital Advisors LLC (3.86M shares), VANGUARD GROUP INC (3.73M shares), BlackRock Inc. (3.33M shares), BAKER BROS. ADVISORS LP (2.88M shares), STATE STREET CORP (2.73M shares), and Redmile Group, LLC (2.41M shares).
This table shows the top 121 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.